SCC is a squamous cell carcinoma antigen, a tumor glycoprotein antigen obtained by isolation from squamous epithelial cell carcinoma of the uterine cervix. It is highly specific for most squamous epithelial cell carcinomas, with elevated levels of SCC in the serum of more than 70% of patients with cervical cancer, compared to about 15% of patients with cervical adenocarcinoma, and 40%-50% of patients with squamous epithelial cell carcinoma of the vulva as well as the vagina. the level of SCC is also related to the progression of the disease and the clinical stage of patients with squamous cell carcinoma of the uterine cervix. If the tumor significantly invades the lymph nodes, SCC will be significantly higher. SCC can also be used as one of the indicators to assess the efficacy of patients with cervical cancer. when the level of SCC continues to rise after chemotherapy, it indicates that the response to chemotherapy is not sensitive and the chemotherapy regimen should be changed or other treatment methods should be used instead. the sensitivity of SCC in predicting recurrent cervical cancer can also reach 65%-85%, so SCC Therefore, SCC is useful for cervical cancer patients to determine prognosis and monitor disease progression.